Non-Invasive Cancer Diagnostics Market Size by 2030

Views:
 
Category: Entertainment
     
 

Presentation Description

Nearly 300 non-invasive diagnostic tests, designed for the detection of various types of cancers, are either already available in the market or under development across the world

Comments

Presentation Transcript

slide 1:

The Non-Invasive Cancer Diagnostics Market Is Projected to Grow At An Annualized Rate Of 20 Till 2030 Roots Analysis has done a detailed study on Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market 3rd Edition 2019-2030: Focus on Circulating Tumor Markers such as CTCs ctDNA cfDNA Exosomes and Other Biomarkers covering key aspects of the industry’s evolution and identifying potential future growth opportunities. Key Market Insights  Presently nearly 300 non-invasive diagnostic tests designed for the detection of various types of cancers are either already available in the market or under development across the world  Several modern diagnostic tests claim to be capable of offering results in relatively short time periods thereby facilitating early diagnosis that is particularly beneficial in the treatment of different types of cancers  Over time big pharma players have initiated product development programs having invested significant capital time and effort on non-invasive diagnostic solutions for use across different oncological indications  Investors having realized the untapped opportunity within this emerging segment of the cancer diagnostics market have invested over USD 3 billion across 120 instances in the period between 2015 and 2019  The growing interest in this field is also reflected in the partnership activity deals inked in the recent past are focused on a diverse range of tumor markers involving both international and indigenous stakeholders  The projected future opportunity is anticipated to be driven by increasing patient population and distributed across various disease indications and application areas across key geographies  These tests are capable of detecting diverse tumor markers that cater to the needs of different stakeholders in fact opinions of industry experts confirm the vast potential of liquid biopsies in disease diagnosis / monitoring For more information please visit https://www.rootsanalysis.com/reports/view_document/liquid-biopsy-and- nicd-market/279.html Table of Contents 1. PREFACE 1.1. Scope of the Report 1.2. Research Methodology 1.3. Chapter Outlines

slide 2:

2. EXECUTIVE SUMMARY 3. INTRODUCTION 3.1. Chapter Overview 3.2. Cancer Statistics and Burden of the Disease 3.3. Importance of Early Cancer Detection 3.4. Cancer Screening and Diagnosis 3.5. Conventional Invasive Cancer Diagnostic Tests 3.5.1. Biopsy 3.5.1.1. Fine Needle Aspiration Biopsy 3.5.1.2. Core Needle Biopsy 3.5.1.3. Vacuum-Assisted Biopsy 3.5.1.4. Image-Guided Biopsy 3.5.1.5. Sentinel Node Biopsy 3.5.1.6. Surgical Biopsy 3.5.1.7. Endoscopic Biopsy 3.5.1.8. Bone Marrow Biopsy 3.5.2. Endoscopy 3.6. Need for Non-Invasive Approaches 3.7. Liquid Biopsy: Diagnosing Circulating Biomarkers 3.7.1. Circulating Tumor Cells 3.7.2. Circulating Tumor DNA 3.7.3. Exosomes 3.8. Costs and Benefits Associated with Liquid Biopsy and Non-Invasive Tests 3.9. Emerging Trends in Intellectual Property Related to Non-Invasive Cancer Diagnostics 3.10. Challenges Associated with Non-Invasive Cancer Diagnostics 3.11. Future Perspectives 4. NON-INVASIVE CANCER SCREENING AND DIAGNOSIS 4.1. Chapter Overview 4.2. Diagnostic Imaging 4.2.1. Magnetic Resonance Imaging MRI 4.2.2. Mammography 4.2.3. Bone Scan 4.2.4. Computerized Tomography CT Scan 4.2.5. Integrated Positron Emission Tomography PET-CT Scan 4.2.6. Ultrasound 4.2.7. X-ray Radiography Barium Enema 4.3. Screening Assays 4.3.1. Circulating Tumor Marker Test 4.3.2. Digital Rectal Exam DRE 4.3.3. Fecal Occult Blood Test FOBT 4.3.4. Multigated Acquisition MUGA Scan 4.3.5. Papanicolaou Test and Human Papilloma Virus Test 4.4. Advanced Non-Invasive Approaches 4.4.1. Cytogenetic / Gene Expression Studies 4.4.2. Molecular Signature-based Non-Invasive Methods 4.4.3. Saliva-based Oral Cancer Diagnostics 4.4.4. Vital Staining

slide 3:

4.4.5. Optical Biopsy 4.4.6. Other Diagnostic Techniques 5. MARKET LANDSCAPE 5.1. Chapter Overview 5.2. Liquid Biopsy Products: List of Developers 5.2.1. Analysis by Year of Establishment 5.2.2. Analysis by Company Size and Geographical Location 5.2.3. Leading Players 5.2.4. Analysis by Geography 5.3. Liquid Biopsy Products: List of Available / Under Development Products 5.3.1. Analysis by Status of Development 5.3.2. Analysis by Type of Product 5.3.3. Analysis by Application Area 5.3.4. Analysis by Target Cancer Indication 5.3.5. Analysis by Type of Tumor Marker 5.3.6. Analysis by End User 5.3.7. Analysis by Turnaround Time 5.4. Liquid Biopsy Products: List of Other Products Kits and Consumables 5.5. Liquid Biopsy Products: List of Contract Service Providers 6. COMPANY PROFILES 6.1. Chapter Overview 6.2. Amoy Diagnostics 6.2.1. Company Overview 6.2.2. Financial Information 6.2.3. Liquid Biopsy Product Portfolio 6.2.4. Recent Developments and Future Outlook 6.3. DiaCarta 6.3.1. Company Overview 6.3.2. Liquid Biopsy Product Portfolio 6.3.3. Recent Developments and Future Outlook 6.4. HaploX 6.4.1. Company Overview 6.4.2. Liquid Biopsy Product Portfolio 6.4.3. Recent Developments and Future Outlook 6.5. NeoGenomics 6.5.1. Company Overview 6.5.2. Financial Information 6.5.3. Liquid Biopsy Product Portfolio 6.5.4. Recent Developments and Future Outlook 6.6. QIAGEN 6.6.1. Company Overview 6.6.2. Financial Information 6.6.3. Liquid Biopsy Product Portfolio 6.6.4. Recent Developments and Future Outlook 6.7. Swift Biosciences 6.7.1. Company Overview 6.7.2. Liquid Biopsy Product Portfolio 6.7.3. Recent Developments and Future Outlook

slide 4:

6.8. Sysmex Inostics 6.8.1. Company Overview 6.8.2. Liquid Biopsy Product Portfolio 6.8.3. Recent Developments and Future Outlook 6.9. Thermo Fisher Scientific 6.9.1. Company Overview 6.9.2. Financial Information 6.9.3. Liquid Biopsy Product Portfolio 6.9.4. Recent Developments and Future Outlook 7. PARTNERSHIPS AND COLLABORATIONS 7.1. Chapter Overview 7.2. Partnership Models 7.3. List of Partnerships and Collaborations 7.3.1. Analysis by Year of Partnership 7.3.2. Analysis by Type of Partnership 7.3.3. Analysis by Type of Tumor Marker 7.3.4. Analysis by Target Cancer Indication 7.3.5. Analysis by Type of Partner 7.3.6. Most Active Players: Analysis by Number of Partnerships 7.3.7. Regional Analysis 7.3.7.1. Intercontinental and Intracontinental Agreements 8. FUNDING AND INVESTMENT ANALYSIS 8.1. Chapter Overview 8.2. Types of Funding 8.3. List of Funding and Investment Instances 8.3.1. Analysis by Number of Funding Instances 8.3.2. Analysis by Amount Invested 8.3.3. Analysis by Type of Funding 8.3.4. Analysis by Target Cancer Indication 8.3.5. Analysis by Type of Tumor Marker 8.3.6. Most Active Players: Analysis by Amount Invested 8.3.7. Most Active Investors: Analysis by Number of Funding Instances 8.3.8. Regional Analysis by Amount Invested 8.4. Concluding Remarks 9. LIQUID BIOPSY: INITIATIVES OF BIG PHARMA PLAYERS 9.1. Chapter Overview 9.2. Top Pharmaceutical Companies 9.2.1. Analysis by Status of Development 9.2.2. Analysis by Type of Tumor Marker 9.2.3. Analysis by Application Area 9.2.4. Analysis by Target Cancer Indication 10. KEY ACQUISITION TARGETS 10.1. Chapter Overview 10.2. Scope and Methodology 10.3. Scoring Criteria and Key Assumptions 10.4. Potential Strategic Acquisition Targets in North America 10.5. Potential Strategic Acquisition Targets in Europe 10.6. Potential Strategic Acquisition Targets in Asia-Pacific / Rest of the World

slide 5:

10.7. Concluding Remarks 11. OTHER NON-INVASIVE CANCER DIAGNOSTICS 11.1. Chapter Overview 11.2. Non-Blood-based Biomarker Detection Tests 11.3. FOBT and Fecal Immunochemical Tests FIT 11.4. Pigmented Lesion Assays 11.5. Stool DNA sDNA-based Tests 11.6. Volatile Organic Compound VOC Detection Tests 11.7. Other Non-Invasive Cancer Diagnostics: Market Landscape 12. MARKET SIZING AND OPPORTUNITY ANALYSIS 12.1. Chapter Overview 12.2. Key Assumptions and Forecast Methodology 12.3. Global Non-Invasive Cancer Diagnostics Market 2019-2030 12.3.1. Global Liquid Biopsy Market 2019-2030 12.3.1.1. Global Liquid Biopsy Market: Distribution by Application Area 2019-2030 12.3.1.1.1. Global Liquid Biopsy Market for Early Diagnosis 2019-2030 12.3.1.1.2. Global Liquid Biopsy Market for Patient Monitoring 2019- 2030 12.3.1.1.3. Global Liquid Biopsy Market for Recurrence Monitoring 2019-2030 12.3.1.2. Global Liquid Biopsy Market: Distribution by Target Cancer Indication 2019-2030 12.3.1.2.1. Global Liquid Biopsy Market for Breast Cancer 2019-2030 12.3.1.2.2. Global Liquid Biopsy Market for Lung Cancer 2019-2030 12.3.1.2.3. Global Liquid Biopsy Market for Colorectal Cancer 2019- 2030 12.3.1.2.4. Global Liquid Biopsy Market for Prostate Cancer 2019-2030 12.3.1.2.5. Global Liquid Biopsy Market for Bladder Cancer 2019-2030 12.3.1.2.6. Global Liquid Biopsy Market for Melanoma 2019-2030 12.3.1.2.7. Global Liquid Biopsy Market for Gastric Cancer 2019-2030 12.3.1.2.8. Global Liquid Biopsy Market for Pancreatic Cancer 2019- 2030 12.3.1.2.9. Global Liquid Biopsy Market for Ovarian Cancer 2019-2030 12.3.1.3. Global Liquid Biopsy Market: Distribution by Type of Tumor Marker 2019-2030 12.3.1.3.1. Global Liquid Biopsy Market for ctDNA 2019-2030 12.3.1.3.2. Global Liquid Biopsy Market for cfDNA 2019-2030 12.3.1.3.3. Global Liquid Biopsy Market for CTCs 2019-2030 12.3.1.3.4. Global Liquid Biopsy Market for Exosomes 2019-2030 12.3.1.3.5. Global Liquid Biopsy Market for Other Tumor Markers 2019- 2030 12.3.1.4. Global Liquid Biopsy Market: Distribution by Type of Analyte 2019- 2030 12.3.1.4.1. Global Liquid Biopsy Market for Blood 2019-2030 12.3.1.4.2. Global Liquid Biopsy Market for Other Body Fluids 2019- 2030 USD Billion

slide 6:

12.3.1.5. Global Liquid Biopsy Market: Distribution by End User 2019-2030 12.3.1.5.1. Global Liquid Biopsy Market for Hospitals 2019-2030 12.3.1.5.2. Global Liquid Biopsy Market for Research Institutes 2019- 2030 12.3.1.5.3. Global Liquid Biopsy Market for Other End Users 2019-2030 12.3.1.6. Global Liquid Biopsy Market: Distribution by Geography 2019-2030 12.3.1.6.1. Liquid Biopsy Market in the US 2019-2030 12.3.1.6.2. Liquid Biopsy Market in the UK 2019-2030 12.3.1.6.3. Liquid Biopsy Market in Germany 2019-2030 12.3.1.6.4. Liquid Biopsy Market in France 2019-2030 12.3.1.6.5. Liquid Biopsy Market in Italy 2019-2030 12.3.1.6.6. Liquid Biopsy Market in Spain 2019-2030 12.3.1.6.7. Liquid Biopsy Market in Japan 2019-2030 12.3.1.6.8. Liquid Biopsy Market in China 2019-2030 12.3.1.6.9. Liquid Biopsy Market in India 2019-2030 12.3.1.6.10. Liquid Biopsy Market in Australia 2019-2030 12.3.2. Other Non-Invasive Cancer Diagnostics Market Forecast 2019- 2030 13. SURVEY INSIGHTS 13.1. Chapter Overview 13.2. Company Specifics of Respondents 13.3. Designation of Respondents 13.4. Type of Product Portfolio 13.5. Types of Products / Services Offered 13.6. Application Area 13.7. Status of Development of the Products 13.8. Likely Market Size 14. CONCLUSION 14.1. Timely Disease Detection and Subsequent Monitoring are Critical Elements of Patient Care 14.1.1. in the Field of Oncology 14.2. Introduction of Sophisticated Molecular Diagnostics has Facilitated Better Cancer 14.2.1. Management 14.3. Liquid Biopsy has Emerged as a Reliable Alternative to the Invasive Methods of Diagnosis 14.4. The Versatile and Patient Friendly Nature of these Diagnostic Tools Cater to a Wide Range 14.4.1. of Applications 14.5. The Interest is Gradually Rising with Participation of Several Start-ups Across Different 14.5.1. Geographies 14.6. In Addition to Liquid Biopsy Development of Other Non-Invasive Tests will Further 14.6.1. Strengthen the Ongoing Innovation 14.7. Rising Venture Capital Support is Indicative of a Lucrative Future Potential 14.8. Primarily Led by Liquid Biopsy the Non-Invasive Cancer Diagnostics Market has Emerged

slide 7:

14.8.1. as a Multi-Billion Dollar Market 15. EXECUTIVE INSIGHTS 15.1. Chapter Overview 15.2. Interview Transcript: Shibichakravarthy Kannan Founder Chief Executive Officer 15.2.1. Theranosis Life Sciences 15.3. Interview Transcript: Anton Iliuk President and Chief Technology Officer Tymora Analytical 15.3.1. Operations 15.4. Interview Transcript: Peter French Strategic Technology Advisor Sienna Cancer 15.4.1. Diagnostics 15.5. Interview Transcript: Joachim Fluhrer Founder and Medical Director Genostics 15.6. Interview Transcript: Brad Walsh Chief Executive Officer Minomic International 15.7. Interview Transcript: Catalina Vasquez Chief Operating Officer Nanostics 15.8. Interview Transcript: Burkhard Jansen Chief Medical Officer DermTech 15.9. Interview Transcript: Frank Szczepanski President and CEO IVDiagnostics 15.10. Interview Transcript: Riccardo Razzini Sales and Marketing Manager LCM Genect 15.11. Interview Transcript: Nathalie Bernard Marketing Director OncoDNA 15.12. Interview Transcript: Abizar Lakdawalla Founder Proxeom 15.13. Interview Transcript: Mark Li CEO Resolution Bioscience 15.14. Interview Transcript: Christer Ericsson Chief Scientific Officer iCellate Medical 15.15. Interview Transcript: Philippe Nore CEO and Co-founder MiNDERA 15.16. Interview Transcript: Jake Micallef Chief Scientific Officer VolitionRx 16. APPENDIX 1: TABULATED DATA 17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS About Roots Analysis Roots Analysis is one of the fastest growing market research companies sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. Contact Information Roots Analysis Private Limited Gaurav Chaudhary +1 415 800 3415 Gaurav.Chaudharyrootsanalysis.com

authorStream Live Help